Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 1,574 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period B Clear all

Conditions: Moderate Chronic Plaque Psoriasis, Severe Chronic Plaque Psoriasis, Mixed Guttate/Plaque Psoriasis
Interventions: Certolizumab pegol, Placebo; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 15
States / cities: Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 12 more

Conditions: Primary Extra-cranial Solid Tumor, Recurrent or Refractory Glypican 3 (GPC3)
Interventions: Codrituzumab; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma, Burkitt Lymphoma, Anaplastic Large-Cell Lymphoma, Gray Zone Lymphoma
Interventions: Etoposide, Rituximab, Prednisone, Cyclophosphamide, Vincristine, Doxorubicin, MRI, CT, Biopsy, PET scan, Laparotomy, Ondansetron, Prochlorperazine, Omeprazole, Docusate Sodium + Sennosides, Lactulose; Drug · Biological · Diagnostic Test + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1993 – 2024
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Baltimore, Maryland • Bethesda, Maryland + 2 more

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 0 Years to 40 Years
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 22
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 19 more

Conditions: Parkinson Disease
Interventions: Mediterranean Diet; Other
Lead sponsor: University of Florida; Other
Eligibility: 21 Years to 85 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Healthy
Interventions: Seltorexant 40 mg, Seltorexant 20 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Rheumatoid Arthritis
Interventions: Atorvastatin, Pravastatin, Rosuvastatin, Filgotinib; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Sjögrens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis
Interventions: VAY736 1ml PFS, VAY736 2 ml PFS, VAY736 2ml AI; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 17
States / cities: Anniston, Alabama • Fullerton, California • La Palma, California + 14 more

Conditions: Renal Impairment
Interventions: S-1/Cisplatin; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 9
States / cities: Scottsdale, Arizona • Los Angeles, California • Santa Monica, California + 6 more

Conditions: Healthy
Interventions: TRV130, Moxifloxacin, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Safety, and Tolerability
Interventions: DHE inhalation powder low dose administered via dry powder inhaler (DPI) device, DHE inhalation powder high dose administered via dry powder inhaler (DPI) device, DHE injected intravenously (1 mg), DHE 2 mg administered by nasal spray (Migranal®), Metoclopramide 10mg; Combination Product · Drug
Lead sponsor: Aspeya Switzerland SA; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Healthy
Interventions: Ramipril10 mg Capsules, single dose, Atlace® 10 mg capsules, single dose; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: TAK-279, Erythromycin, Phenytoin, Efavirenz; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy
Interventions: Part A, Part B; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cypress, California

Conditions: Prostate Cancer
Interventions: Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls, Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Male only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure, Renal Insufficiency
Interventions: Cenderitide, Placebo; Drug
Lead sponsor: Capricor Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Tustin, California

Conditions: Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder
Interventions: N-Acetyl cysteine, Placebo; Drug
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 60 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Drug Interaction, Healthy Volunteer
Interventions: Entinostat, Midazolam; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: Use electronic cigarette or smoke conventional cigarette; Other
Lead sponsor: British American Tobacco (Investments) Limited; Industry
Eligibility: 21 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Burbank, California

Conditions: HIV Counseling and Testing, HIV Risk Behavior, HIV Prevention
Interventions: Healthcare counseling service; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 49 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Knee Osteoarthritis (Knee OA), Chronic Pain, Chronic Knee Pain
Interventions: Duloxetine, Placebo; Drug
Lead sponsor: Benedict Alter; Other
Eligibility: 45 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Atopic Dermatitis
Interventions: PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction
Interventions: Ipilimumab, Best Supportive care (BSC); Biological · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 4
States / cities: Miami Beach, Florida • New York, New York • Houston, Texas

Conditions: Functional Abdominal Pain, Functional Dyspepsia, Irritable Bowel Syndrome, Functional Gastrointestinal Disorders
Interventions: Placebo Suspension, Hyoscyamine; Other · Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 21 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated Mothers

Dietary Intervention and Gastrointestinal Function in Patients With Parkinson's Disease

A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions

Study to Evaluate Organic Anion Transporting Polypeptide (OATP) Transporter-Mediated Drug-Drug Interactions Between Filgotinib and Statins as Probe Drugs in Healthy Participants

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Evaluating Patients With Varying Degrees of Renal Function

Study of the Effects of TRV130, at Therapeutic and Supra Therapeutic Doses, on QTc Intervals

A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults

Surufatinib DDI With a PPI and a CYP3A Inducer

Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program

Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment

Evaluating the Hypothesized Mechanism of Action of N-acetylcysteine for Bipolar Disorder

A Study to Examine the Effects of Entinostat on Midazolam in Healthy Adult Subjects

Pharmacokinetic Study Comparing Nicotine Delivery From E-cigarettes and a Conventional Cigarette in Healthy Subjects

Safe Spaces 4 Sexual Health

Personalized Analgesia Through Central Nervous System Engagement to Unlock Performance

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy

Efficacy of Open Label Placebo in Children With FGIDs